LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article ; Online: Dysplasia and DNA ploidy to prognosticate clinical outcome in oral potentially malignant disorders.

Sathasivam, Hans Prakash / Nayar, Deepa / Sloan, Philip / Thomson, Peter J / Odell, Edward W / Robinson, Max

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology

2021 Volume 50, Issue 2, Page(s) 200–209

Abstract: Background: Oral potentially malignant disorders are a clinical conundrum as there are no reliable methods to predict their behaviour. We combine conventional oral epithelial dysplasia grading with DNA ploidy analysis to examine the validity of this ... ...

Abstract	Background: Oral potentially malignant disorders are a clinical conundrum as there are no reliable methods to predict their behaviour. We combine conventional oral epithelial dysplasia grading with DNA ploidy analysis to examine the validity of this approach to risk assessment in a cohort of patients with known clinical outcomes. Methods: Sections from diagnostic biopsies were assessed for oral epithelial dysplasia using the WHO grading system, and DNA ploidy analysis was performed using established methods. Patients reviewed for a minimum of 5 years who did not develop oral squamous cell carcinoma were classified as "non-transforming" cases. Patients that developed oral squamous cell carcinoma ≥ 6 months after the initial diagnostic biopsy were classified as having "malignant transformation." Results: Ninety cases were included in the study. Seventy cases yielded informative DNA ploidy results. Of these 70 cases, 31 progressed to cancer. Oral epithelial dysplasia grading and DNA ploidy status were both significantly associated with clinical outcome (P < 0.05). Severe dysplasia had a hazard ratio of 3.50 (CI: 1.46, 8.45; P = 0.005) compared to cases with mild dysplasia. Aneuploidy had a hazard ratio of 2.09 (CI: 1.01, 4.32; P = 0.046) compared to cases with a diploid/tetraploid status. Receiver operating characteristic analysis gave an area under the curve of 0.617 for DNA ploidy status and 0.688 when DNA ploidy status was combined with dysplasia grading. Conclusion: Our findings suggest that combining dysplasia grading with DNA ploidy status has clinical utility which could be used to develop novel management algorithms.
MeSH term(s)	Carcinoma, Squamous Cell/genetics ; DNA ; Humans ; Leukoplakia, Oral/genetics ; Mouth Neoplasms/genetics ; Ploidies ; Precancerous Conditions/genetics ; Prognosis
Chemical Substances	DNA (9007-49-2)
Language	English
Publishing date	2021-01-05
Publishing country	Denmark
Document type	Journal Article
ZDB-ID	1021270-x
ISSN	1600-0714 ; 0904-2512
ISSN (online)	1600-0714
ISSN	0904-2512
DOI	10.1111/jop.13121
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 825: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: A multicentre evaluation and expert recommendations of use of the newly developed BioFire Joint Infection polymerase chain reaction panel.

Saeed, Kordo / Ahmad-Saeed, Nusreen / Annett, Rachel / Barlow, Gavin / Barrett, Lucinda / Boyd, Sara E / Boran, Nicola / Davies, Peter / Hughes, Harriet / Jones, Gwennan / Leach, Laura / Lynch, Maureen / Nayar, Deepa / Maloney, Robert J / Marsh, Martin / Milburn, Olivia / Mitchell, Shanine / Moffat, Lynn / Moore, Luke S P /

Murphy, Michael E / O'Shea, Shaan Ashk / O'Sullivan, Fionnuala / Peach, Teresa / Petridou, Christina / Reidy, Niamh / Selvaratnam, Mathyruban / Talbot, Ben / Taylor, Vanessa / Wearmouth, Deborah / Aldridge, Catherine

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

2022 Volume 42, Issue 2, Page(s) 169–176

Abstract: Septic arthritis is a serious condition with significant morbidity and mortality, routinely diagnosed using culture. The FDA has recently approved the rapid molecular BioFire® Joint Infection Panel (BJIP) for synovial fluid. We aimed to evaluate the BJIP ...

Abstract	Septic arthritis is a serious condition with significant morbidity and mortality, routinely diagnosed using culture. The FDA has recently approved the rapid molecular BioFire® Joint Infection Panel (BJIP) for synovial fluid. We aimed to evaluate the BJIP compared to culture and its potential use in patient management. A multicentre retrospective evaluation of BJIP was conducted in the UK and Ireland. Positive percent agreement (PPA) and negative percent agreement (NPA) were calculated between the BJIP and routine culture. A multidisciplinary team (MDT) discussion addressing the optimal or potential case use of the assay practice was facilitated. Three hundred ninety-nine surplus synovial fluid samples (~ 70% from native joints) from eight centres were processed using BJIP in addition to routine culture. An increased yield of positive results was detected using BJIP compared to routine culture (98 vs 83), giving an overall PPA of 91.6% and overall NPA of 93% for the BJIP compared to culture results. The BJIP detected resistant markers and additional organisms that could influence antibiotic choices including Neisseria gonorrhoeae and Kingella kingae. The MDT agreed that the assay could be used, in addition to standard methods, in adult and children patients with specialist advice use based on local needs. Rapid results from BJIP were assessed as having potential clinical impact on patient management. Organisms not included in the panel may be clinically significant and may limit the value of this test for PJI.
MeSH term(s)	Child ; Adult ; Humans ; Retrospective Studies ; Arthritis, Infectious/diagnosis ; Arthritis, Infectious/microbiology ; Polymerase Chain Reaction ; Synovial Fluid/microbiology ; Kingella kingae/genetics
Language	English
Publishing date	2022-12-07
Publishing country	Germany
Document type	Multicenter Study ; Journal Article
ZDB-ID	603155-9
ISSN	1435-4373 ; 0934-9723 ; 0722-2211
ISSN (online)	1435-4373
ISSN	0934-9723 ; 0722-2211
DOI	10.1007/s10096-022-04538-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1732: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Potential value of a rapid syndromic multiplex PCR for the diagnosis of native and prosthetic joint infections: a real-world evidence study.

Pascual, Stéphanie / Noble, Brooklyn / Ahmad-Saeed, Nusreen / Aldridge, Catherine / Ambretti, Simone / Amit, Sharon / Annett, Rachel / O'Shea, Shaan Ashk / Barbui, Anna Maria / Barlow, Gavin / Barrett, Lucinda / Berth, Mario / Bondi, Alessandro / Boran, Nicola / Boyd, Sara E / Chaves, Catarina / Clauss, Martin / Davies, Peter / Dianzo-Delgado, Ileana T /

Esteban, Jaime / Fuchs, Stefan / Friis-Hansen, Lennart / Goldenberger, Daniel / Golle, Andrej / Groonroos, Juha O / Hoffmann, Ines / Hoffmann, Tomer / Hughes, Harriet / Ivanova, Marina / Jezek, Peter / Jones, Gwennan / Ceren Karahan, Zeynep / Lass-Flörl, Cornelia / Laurent, Frédéric / Leach, Laura / Horsbøll Pedersen, Matilde Lee / Loiez, Caroline / Lynch, Maureen / Maloney, Robert J / Marsh, Martin / Milburn, Olivia / Mitchell, Shanine / Moore, Luke S P / Moffat, Lynn / Murdjeva, Marianna / Murphy, Michael E / Nayar, Deepa / Nigrisoli, Giacomo / O'Sullivan, Fionnuala / Öz, Büşra / Peach, Teresa / Petridou, Christina / Prinz, Mojgan / Rak, Mitja / Reidy, Niamh / Rossolini, Gian Maria / Roux, Anne-Laure / Ruiz-Garbajosa, Patricia / Saeed, Kordo / Salar-Vidal, Llanos / Salas Venero, Carlos / Selvaratnam, Mathyruban / Senneville, Eric / Starzengruber, Peter / Talbot, Ben / Taylor, Vanessa / Trebše, Rihard / Wearmouth, Deborah / Willinger, Birgit / Wouthuyzen-Bakker, Marjan / Couturier, Brianne / Allantaz, Florence

Journal of bone and joint infection

2024 Volume 9, Issue 1, Page(s) 87–97

Abstract: ... ...

Abstract	Introduction
Language	English
Publishing date	2024-02-28
Publishing country	Germany
Document type	Journal Article
ISSN	2206-3552
ISSN	2206-3552
DOI	10.5194/jbji-9-87-2024
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: Potential value of a rapid syndromic multiplex PCR for the diagnosis of native and prosthetic joint infections

Pascual, Stéphanie / Noble, Brooklyn / Ahmad-Saeed, Nusreen / Aldridge, Catherine / Ambretti, Simone / Amit, Sharon / Annett, Rachel / O'Shea, Shaan Ashk / Barbui, Anna Maria / Barlow, Gavin / Barrett, Lucinda / Berth, Mario / Bondi, Alessandro / Boran, Nicola / Boyd, Sara E. / Chaves, Catarina / Clauss, Martin / Davies, Peter / Dianzo-Delgado, Ileana T. /

Esteban, Jaime / Fuchs, Stefan / Friis-Hansen, Lennart / Goldenberger, Daniel / Golle, Andrej / Groonroos, Juha O. / Hoffmann, Ines / Hoffmann, Tomer / Hughes, Harriet / Ivanova, Marina / Jezek, Peter / Jones, Gwennan / Ceren Karahan, Zeynep / Lass-Flörl, Cornelia / Laurent, Frédéric / Leach, Laura / Horsbøll Pedersen, Matilde Lee / Loiez, Caroline / Lynch, Maureen / Maloney, Robert J. / Marsh, Martin / Milburn, Olivia / Mitchell, Shanine / Moore, Luke S. P. / Moffat, Lynn / Murdjeva, Marianna / Murphy, Michael E. / Nayar, Deepa / Nigrisoli, Giacomo / O'Sullivan, Fionnuala / Öz, Büşra / Peach, Teresa / Petridou, Christina / Prinz, Mojgan / Rak, Mitja / Reidy, Niamh / Rossolini, Gian Maria / Roux, Anne-Laure / Ruiz-Garbajosa, Patricia / Saeed, Kordo / Salar-Vidal, Llanos / Salas Venero, Carlos / Selvaratnam, Mathyruban / Senneville, Eric / Starzengruber, Peter / Talbot, Ben / Taylor, Vanessa / Trebše, Rihard / Wearmouth, Deborah / Willinger, Birgit / Wouthuyzen-Bakker, Marjan / Couturier, Brianne / Allantaz, Florence

eISSN: 2206-3552

a real-world evidence study

2024

Abstract: Introduction : The BIOFIRE Joint Infection (JI) Panel is a diagnostic tool that uses multiplex-PCR testing to detect microorganisms in synovial fluid specimens from patients suspected of having septic arthritis (SA) on native joints or prosthetic joint ... ...

Abstract	Introduction : The BIOFIRE Joint Infection (JI) Panel is a diagnostic tool that uses multiplex-PCR testing to detect microorganisms in synovial fluid specimens from patients suspected of having septic arthritis (SA) on native joints or prosthetic joint infections (PJIs). Methods : A study was conducted across 34 clinical sites in 19 European and Middle Eastern countries from March 2021 to June 2022 to assess the effectiveness of the BIOFIRE JI Panel. Results : A total of 1527 samples were collected from patients suspected of SA or PJI, with an overall agreement of 88.4 % and 85 % respectively between the JI Panel and synovial fluid cultures (SFCs). The JI Panel detected more positive samples and microorganisms than SFC, with a notable difference on Staphylococcus aureus , Streptococcus species, Enterococcus faecalis , Kingella kingae , Neisseria gonorrhoeae , and anaerobic bacteria. The study found that the BIOFIRE JI Panel has a high utility in the real-world clinical setting for suspected SA and PJI, providing diagnostic results in approximately 1 h. The user experience was positive, implying a potential benefit of rapidity of results' turnover in optimising patient management strategies. Conclusion : The study suggests that the BIOFIRE JI Panel could potentially optimise patient management and antimicrobial therapy, thus highlighting its importance in the clinical setting.
Subject code	616
Language	English
Publishing date	2024-02-28
Publishing country	de
Document type	Book ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Toxic megacolon complicating Escherichia coli O157 infection.

Nayar, Deepa M / Vetrivel, Shanmu / McElroy, Jack / Pai, Pearl / Koerner, Roland J

The Journal of infection

2006 Volume 52, Issue 4, Page(s) e103–6

Abstract: Toxic megacolon is a well known complication in inflammatory bowel disease such as ulcerative colitis or Crohn's disease. The development of toxic megacolon as a complication of infectious colitis is rare. However it is recognised as a complication of ... ...

Abstract	Toxic megacolon is a well known complication in inflammatory bowel disease such as ulcerative colitis or Crohn's disease. The development of toxic megacolon as a complication of infectious colitis is rare. However it is recognised as a complication of enteric infections caused by Clostridium difficile, Campylobacter jejuni, Shigella, Salmonella species, Cytomegalovirus and amoebae. We describe a case of necrotising haemorrhagic ileo-colitis in a previously fit and healthy young adult female caused by Escherichia coli O157 where toxic megacolon developed as a complication along with hemolytic uremic syndrome (HUS).
MeSH term(s)	Adult ; Anti-Infective Agents/administration & dosage ; Antibodies, Bacterial/blood ; Ciprofloxacin/administration & dosage ; Colitis/microbiology ; Colon/pathology ; Colon/surgery ; Escherichia coli Infections/complications ; Escherichia coli Infections/diagnosis ; Escherichia coli Infections/drug therapy ; Escherichia coli Infections/microbiology ; Escherichia coli O157/immunology ; Escherichia coli O157/isolation & purification ; Female ; Gastrointestinal Hemorrhage/microbiology ; Hemolytic-Uremic Syndrome/etiology ; Humans ; Immunoglobulin M/blood ; Megacolon, Toxic/etiology ; Megacolon, Toxic/surgery ; Metronidazole/administration & dosage ; Treatment Outcome
Chemical Substances	Anti-Infective Agents ; Antibodies, Bacterial ; Immunoglobulin M ; Metronidazole (140QMO216E) ; Ciprofloxacin (5E8K9I0O4U)
Language	English
Publishing date	2006-04
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	424417-5
ISSN	1532-2742 ; 0163-4453
ISSN (online)	1532-2742
ISSN	0163-4453
DOI	10.1016/j.jinf.2005.07.029
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1501: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 48: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A biphasic innate immune MAPK response discriminates between the yeast and hyphal forms of Candida albicans in epithelial cells.

Moyes, David L / Runglall, Manohursingh / Murciano, Celia / Shen, Chengguo / Nayar, Deepa / Thavaraj, Selvam / Kohli, Arinder / Islam, Ayesha / Mora-Montes, Hector / Challacombe, Stephen J / Naglik, Julian R

Cell host & microbe

2010 Volume 8, Issue 3, Page(s) 225–235

Abstract: Discriminating between commensal and pathogenic states of opportunistic pathogens is critical for host mucosal defense and homeostasis. The opportunistic human fungal pathogen Candida albicans is also a constituent of the normal oral flora and grows ... ...

Abstract	Discriminating between commensal and pathogenic states of opportunistic pathogens is critical for host mucosal defense and homeostasis. The opportunistic human fungal pathogen Candida albicans is also a constituent of the normal oral flora and grows either as yeasts or hyphae. We demonstrate that oral epithelial cells orchestrate an innate response to C. albicans via NF-κB and a biphasic MAPK response. Activation of NF-κB and the first MAPK phase, constituting c-Jun activation, is independent of morphology and due to fungal cell wall recognition. Activation of the second MAPK phase, constituting MKP1 and c-Fos activation, is dependent upon hypha formation and fungal burdens and correlates with proinflammatory responses. Such biphasic response may allow epithelial tissues to remain quiescent under low fungal burdens while responding specifically and strongly to damage-inducing hyphae when burdens increase. MAPK/MKP1/c-Fos activation may represent a "danger response" pathway that is critical for identifying and responding to the pathogenic switch of commensal microbes.
MeSH term(s)	Candida albicans/cytology ; Candida albicans/growth & development ; Candida albicans/immunology ; Candida albicans/pathogenicity ; Candidiasis, Oral/immunology ; Cell Line, Tumor ; Cell Wall/immunology ; Cytokines/metabolism ; Dual Specificity Phosphatase 1/metabolism ; Epithelial Cells/immunology ; Epithelial Cells/metabolism ; Epithelial Cells/microbiology ; Fungal Proteins/metabolism ; Host-Pathogen Interactions ; Humans ; Hyphae/immunology ; Mitogen-Activated Protein Kinase 1/metabolism ; Mitogen-Activated Protein Kinases/metabolism ; Mouth Mucosa/immunology ; Mouth Mucosa/metabolism ; Mouth Mucosa/microbiology ; NF-kappa B/metabolism ; Proto-Oncogene Proteins c-fos/metabolism ; Signal Transduction ; Virulence ; Yeasts/metabolism
Chemical Substances	Cytokines ; Fungal Proteins ; NF-kappa B ; Proto-Oncogene Proteins c-fos ; Mitogen-Activated Protein Kinase 1 (EC 2.7.11.24) ; Mitogen-Activated Protein Kinases (EC 2.7.11.24) ; Dual Specificity Phosphatase 1 (EC 3.1.3.48)
Language	English
Publishing date	2010-09-09
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2278004-X
ISSN	1934-6069 ; 1931-3128
ISSN (online)	1934-6069
ISSN	1931-3128
DOI	10.1016/j.chom.2010.08.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6578: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

Thwaites, Guy E / Scarborough, Matthew / Szubert, Alexander / Nsutebu, Emmanuel / Tilley, Robert / Greig, Julia / Wyllie, Sarah A / Wilson, Peter / Auckland, Cressida / Cairns, Janet / Ward, Denise / Lal, Pankaj / Guleri, Achyut / Jenkins, Neil / Sutton, Julian / Wiselka, Martin / Armando, Gonzalez-Ruiz / Graham, Clive / Chadwick, Paul R /

Barlow, Gavin / Gordon, N Claire / Young, Bernadette / Meisner, Sarah / McWhinney, Paul / Price, David A / Harvey, David / Nayar, Deepa / Jeyaratnam, Dakshika / Planche, Tim / Minton, Jane / Hudson, Fleur / Hopkins, Susan / Williams, John / Török, M Estee / Llewelyn, Martin J / Edgeworth, Jonathan D / Walker, A Sarah

Lancet (London, England)

2017 Volume 391, Issue 10121, Page(s) 668–678

Abstract: Background: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or ... ...

Abstract	Background: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. Methods: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. Findings: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). Interpretation: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. Funding: UK National Institute for Health Research Health Technology Assessment.
MeSH term(s)	Administration, Intravenous ; Administration, Oral ; Aged ; Antibiotics, Antitubercular/administration & dosage ; Antibiotics, Antitubercular/pharmacology ; Bacteremia/drug therapy ; Bacteremia/microbiology ; Community-Acquired Infections/drug therapy ; Cross Infection/drug therapy ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Rifampin/administration & dosage ; Rifampin/pharmacology ; Staphylococcal Infections/drug therapy ; Treatment Failure
Chemical Substances	Antibiotics, Antitubercular ; Rifampin (VJT6J7R4TR)
Language	English
Publishing date	2017-12-14
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	3306-6
ISSN	1474-547X ; 0023-7507 ; 0140-6736
ISSN (online)	1474-547X
ISSN	0023-7507 ; 0140-6736
DOI	10.1016/S0140-6736(17)32456-X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.5: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 94: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT.

Thwaites, Guy E / Scarborough, Matthew / Szubert, Alexander / Saramago Goncalves, Pedro / Soares, Marta / Bostock, Jennifer / Nsutebu, Emmanuel / Tilley, Robert / Cunningham, Richard / Greig, Julia / Wyllie, Sarah A / Wilson, Peter / Auckland, Cressida / Cairns, Janet / Ward, Denise / Lal, Pankaj / Guleri, Achyut / Jenkins, Neil / Sutton, Julian /

Health technology assessment (Winchester, England)

2018 Volume 22, Issue 59, Page(s) 1–148

Abstract: Background: Staphylococcus aureus: Objectives: To determine whether or not adjunctive rifampicin reduces bacteriological (microbiologically confirmed) failure/recurrence or death through 12 weeks from randomisation. Secondary objectives included ... ...

Abstract	Background: Staphylococcus aureus Objectives: To determine whether or not adjunctive rifampicin reduces bacteriological (microbiologically confirmed) failure/recurrence or death through 12 weeks from randomisation. Secondary objectives included evaluating the impact of rifampicin on all-cause mortality, clinically defined failure/recurrence or death, toxicity, resistance emergence, and duration of bacteraemia; and assessing the cost-effectiveness of rifampicin. Design: Parallel-group, randomised (1 : 1), blinded, placebo-controlled multicentre trial. Setting: UK NHS trust hospitals. Participants: Adult inpatients (≥ 18 years) with meticillin-resistant or susceptible Interventions: Adjunctive rifampicin (600-900 mg/day, oral or intravenous) or placebo for 14 days in addition to standard antibiotic therapy. Investigators and patients were blinded to trial treatment. Follow-up was for 12 weeks (assessments at 3, 7, 10 and 14 days, weekly until discharge and final assessment at 12 weeks post randomisation). Main outcome measures: The primary outcome was all-cause bacteriological (microbiologically confirmed) failure/recurrence or death through 12 weeks from randomisation. Results: Between December 2012 and October 2016, 758 eligible participants from 29 UK hospitals were randomised: 370 to rifampicin and 388 to placebo. The median age was 65 years [interquartile range (IQR) 50-76 years]. A total of 485 (64.0%) infections were community acquired and 132 (17.4%) were nosocomial; 47 (6.2%) were caused by meticillin-resistant Conclusions: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with Future work: Given the substantial mortality, other antibiotic combinations or improved source management should be investigated. Trial registrations: Current Controlled Trials ISRCTN37666216, EudraCT 2012-000344-10 and Clinical Trials Authorisation 00316/0243/001. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in
MeSH term(s)	Aged ; Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/economics ; Anti-Bacterial Agents/therapeutic use ; Bacteremia/drug therapy ; Bacteremia/microbiology ; Bacteremia/mortality ; Cost-Benefit Analysis ; Double-Blind Method ; Drug Resistance, Bacterial/drug effects ; Drug Therapy, Combination ; Female ; Health Expenditures/statistics & numerical data ; Humans ; Male ; Middle Aged ; Models, Econometric ; Quality of Life ; Quality-Adjusted Life Years ; Rifampin/adverse effects ; Rifampin/economics ; Rifampin/therapeutic use ; Staphylococcal Infections/drug therapy ; Staphylococcal Infections/mortality ; Staphylococcus aureus ; United Kingdom
Chemical Substances	Anti-Bacterial Agents ; Rifampin (VJT6J7R4TR)
Language	English
Publishing date	2018-10-31
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2006765-3
ISSN	2046-4924 ; 1366-5278
ISSN (online)	2046-4924
ISSN	1366-5278
DOI	10.3310/hta22590
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5162: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito